Anshun

Researchers are conducting a prospective, multi-center, non-interventional cohort study across China to investigate Drug-induced Liver Injury (DILI). The study aims to explore the clinical characteristics, responsible drugs or herbs, patient outcomes, and risk factors associated with DILI. An important goal is to identify new serum markers that could help predict the prognosis of this condition. The study also seeks to develop and validate a prognostic model incorporating these novel serum markers to improve patient care in China. Participants will be followed in a nationwide standardized cohort with long-term monitoring to collect detailed prognostic data on DILI. The study does not involve experimental treatments but focuses on observation and data collection to help understand DILI better. No specific interventions are delivered as part of this research. During the study, participants will undergo evaluations to confirm diagnosis and monitor their liver health over time. Researchers will measure primary outcomes including death or liver transplantation within one year and the occurrence of acute liver failure within one year. The study involves ongoing assessments to gather clinical data and validate the prognostic model based on novel serum biomarkers, aiming to enhance future management of DILI.

Researchers are conducting a multicenter observational study to better understand the treatment outcomes for patients diagnosed with psoriasis by dermatologists in clinic settings across China. Psoriasis is a chronic, recurrent inflammatory disease influenced by genetic and environmental factors, presenting as erythematosquamous lesions and potentially affecting multiple organs. The study aims to compare the effectiveness of various treatments chosen by patients, including phototherapy, traditional systemic therapies, and biologics, in real-world clinical practice. This non-interventional study allows patients to select their preferred treatment without restrictions. Data is collected primarily through a phone application called "Psoriasis New World," enabling continuous monitoring of patient progress. The study evaluates multiple outcomes such as the Psoriasis Area and Severity Index (PASI), which measures skin lesion severity and body area involvement, along with the Physician Global Assessment, Investigator Global Assessment, Body Surface Area affected, and Dermatology Life Quality Index. Patient safety is monitored throughout, including the recording of any adverse events and laboratory tests such as liver function. Participants will be followed over six months to measure the percentage achieving complete clearance of psoriasis symptoms (PASI 100). Regular assessments of disease severity and quality of life changes will be conducted remotely via the app. Continuous safety monitoring ensures any side effects or complications are documented. This approach provides comprehensive real-world evidence on how different psoriasis treatments perform in routine clinical care.